Impact of pre-operative transarterial embolization on the treatment of hepatocellular carcinoma with liver transplantation

Figure 1 Staging of hepatocellular carcinoma before and after TAE. Twenty-nine patients received embolization before liver transplantation. Seven patients exceeding criteria (group A2) (outside the box) were downgraded to acceptable limits (inside the box with arrow).

Figure 2 The 5-year actuarial survival rate of patients with hepatocellular carcinoma after liver transplantation.

Figure 3 Patient and graft survival by Kaplan-Meier analysis shows higher 4-year survival in hepatocellular carcinoma that received pre-transplantation TAE (group A) compared to non-TAE (group B). Log-rank: P = 0.95.

Figure 4 Patient and graft survival by Kaplan-Meier analysis shows a higher 3-year survival in patients with hepatocellular carcinoma previously above the Milan criteria and downgraded by TAE (group A2) than the patients that originally met the criteria (group A1 + group B). Log-rank: P = 0.81.

Figure 5 Patient and graft survival by Kaplan-Meier analysis shows a significantly higher 3-year survival in patients with hepatocellular carcinoma with tumor necrosis >85% compared to those with tumor necrosis <85% after TAE. Log-rank: P = 0.060.